Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Squamous Cell Carcinoma of Head and Neck: early-phase trial registry
15 of 38 indexed Squamous Cell Carcinoma of Head and Neck trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #393 of 28,707 conditions by registered trial count.
38 US clinical trials · 15 currently recruiting · #393 of 28,707 conditions by registered trial count
Squamous Cell Carcinoma of Head and Neck: 38 US clinical trials tracked, 15 recruiting.
Squamous Cell Carcinoma of Head and Neck is the subject of 38 registered US clinical trials on ClinicalTrials.gov, 15 of them currently open to new participants. 1 are in Phase 3-4 (later-stage) and 34 in Phase 1-2 (earlier-stage). The most active sponsor is NGM Biopharmaceuticals, running 3 of these trials.
Enrollment posture brief
Registry condition squamous-cell-carcinoma-of-head-and-neck
OPEN 15 | RECR 39% | LATE 1 | EARLY 34 | RANK #393 | SPON 3
Volume-matched condition peers
Nearest open-share peer: Retinitis Pigmentosa (39% recruiting · 38 trials)
Squamous Cell Carcinoma of Head and Neck lists 15 open slots (39% of 38 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Squamous Cell Carcinoma of Head and Neck on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Squamous Cell Carcinoma of Head and Neck recruits in line with its size-band peers.
15 of 38 indexed trials (39.5%) are open to enrollment, against a 39.7% average across 762 conditions with 20-99 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
Sponsorship of Squamous Cell Carcinoma of Head and Neck trials is spread across many organizations.
NGM Biopharmaceuticals accounts for 3 of 38 trials (7.9%). 33 distinct sponsors appear on at least one study for this condition label.
-
Typical Squamous Cell Carcinoma of Head and Neck enrolment sits around 71 participants.
Median target enrolment is 71 among the 38 trials that report a genuine target (sentinel values excluded). 22 of those (57.9%) plan for fewer than 100 participants.
-
Squamous Cell Carcinoma of Head and Neck research is mostly interventional.
35 interventional and 3 observational studies make up this index (92.1% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
38 total, page 1 of 1
A Study of Sigvotatug Vedotin in Advanced Solid Tumors
Seagen, a wholly owned subsidiary of Pfizer
NCT04389632
A Study of BMS-986340 as Monotherapy and in Combination With Nivolumab or Docetaxel in Participants With Advanced Solid Tumors
Bristol-Myers Squibb
NCT04895709
A Study of Amivantamab in Addition to Standard of Care Agents (SOC) Compared With SOC Alone in Participants With Recurrent/Metastatic Head and Neck Cancer
Janssen Research & Development
NCT07276399
A Study of Amivantamab Alone or in Addition to Other Treatment Agents in Participants With Head and Neck Cancer
Janssen Research & Development
NCT06385080
A Study of MGC026 in Participants With Advanced Solid Tumors
MacroGenics
NCT06242470
Tumor-Informed ctDNA Testing for MRD Following Treatment of Squamous Cell Carcinoma
University of California, San Francisco
NCT06606028
A Study to Evaluate the Safety and Tolerability of TOS-358 in Adults With HR+ Breast Cancer and Other Select Solid Tumors
Totus Medicines
NCT05683418
A Study of DM005 in Patients With Advanced Solid Tumors
Doma Biopharmaceutical（Suzhou）Co.
NCT06515990
Candida Therapeutic Vaccine in Head and Neck Cancer Patients to Reduce Recurrence
University of Arkansas
NCT05952934
Measurable Residual Disease Detection Using Tumor-Informed ctDNA Surveillance After Curative-Intent Treatment in HPV-Independent Squamous Cell Carcinoma of the Head and Neck
Massachusetts Eye and Ear Infirmary
NCT06744296
Phase II Trial of Neoadjuvant and Adjuvant IO102-IO103 and Pembrolizumab KEYTRUDA® in Patients With Resectable Tumors
IO Biotech
NCT05280314
5-Azacytidine and/or Nivolumab in Resectable HPV-Associated HNSCC
Barbara Burtness
NCT05317000
A Study of Sacituzumab Govitecan in Combination With Cetuximab in People With Head and Neck Squamous Cell Cancer (HNSCC)
Memorial Sloan Kettering Cancer Center
NCT07063212
A Study of JNJ-90301900 in Combination With Chemoradiation Therapy in Participants With Locally Advanced Head and Neck Squamous Cell Carcinoma
Johnson & Johnson Enterprise Innovation
NCT07219212
Drug Screening Using Novel IMD in Salivary and Head and Neck Cancers
Brigham and Women's Hospital
NCT05553782
A Study Evaluating AB248 Alone or in Combination With Pembrolizumab in Adult Patients With Solid Tumors
Asher Biotherapeutics
NCT05653882
MicroRNA Markers in Head and Neck Cancers
University of Colorado, Denver
NCT04305366
Study of NGM707 As Monotherapy and in Combination with Pembrolizumab in Advanced or Metastatic Solid Tumor Malignancies
NGM Biopharmaceuticals
NCT04913337
NBTXR3 Activated by Radiotherapy for Patients With Advanced Cancers Treated With An Anti-PD-1 Therapy
Nanobiotix
NCT03589339
Study of NGM831 as Monotherapy and in Combination With Pembrolizumab or Pembrolizumab and NGM438 in Advanced or Metastatic Solid Tumors
NGM Biopharmaceuticals
NCT05215574
A Clinical Trial Evaluating TG4050 in Head and Neck Cancer
Transgene
NCT04183166
Study of NGM438 as Monotherapy and in Combination With Pembrolizumab in Advanced or Metastatic Solid Tumors
NGM Biopharmaceuticals
NCT05311618
HYPORT: A Phase I/II Study of Hypofractionated Post-operative Radiation Therapy for Head and Neck Cancer
University of Texas Southwestern Medical Center
NCT04403620
Pembrolizumab Plus Olaparib in LA-HNSCC
UNC Lineberger Comprehensive Cancer Center
NCT05366166
Study of Xevinapant With Radiation and Chemotherapy for Patients With Head and Neck Cancer
University of Chicago
NCT06110195
A Phase 1b Study of WU-NK-101 in Combination With Cetuximab
Wugen
NCT05674526
Pilot Study of Imatinib Cetuximab Combo for H & N Cancer
University of Wisconsin, Madison
NCT05816785
ASP-1929 Photoimmunotherapy (PIT) Study in Patients With Recurrent Head/Neck Cancer
Rakuten Medical
NCT05182866
TBio-4101 and Pembro wi/ or w/o Chemo in Recurrent/Metastatic HNSCC
H. Lee Moffitt Cancer Center and Research Institute
NCT06236425
Lenvatinib (E7080/MK-7902) in Combination With Pembrolizumab (MK-3475) vs. Standard Chemotherapy and Lenvatinib Monotherapy in Participants With Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma That Progressed After Platinum Therapy and Immunotherapy (MK-7902-009/E7080-G000-228/LEAP-009)
Merck Sharp & Dohme
NCT04428151
A Study of Atezolizumab Plus Tiragolumab and Atezolizumab Plus Placebo as First-Line Treatment in Participants With Recurrent/Metastatic PD-L1 Positive Squamous Cell Carcinoma of the Head and Neck
Hoffmann-La Roche
NCT04665843
INCB106385 Alone or in Combination With Immunotherapy in Advanced Solid Tumors
Incyte Corporation
NCT04580485
A Study to Evaluate NT219 Alone and in Combination with ERBITUX® (Cetuximab) in Adults with Advanced Solid Tumors and Head and Neck Cancer
TyrNovo
NCT04474470
TPST-1120 as Monotherapy and in Combination With Nivolumab in Subjects With Advanced Cancers
Tempest Therapeutics
NCT03829436
A Study of ALKS 4230 (Nemvaleukin Alfa) With Pembrolizumab in Head and Neck Cancer
Mural Oncology
NCT04144517
Radiotherapy in Combination With Atezolizumab Prior to Surgical Resection for HPV Unrelated HNSCC
University of Colorado, Denver
NCT05053737
GEN-001 (Live Biotherapeutic Product) and Avelumab Combination Study for Patients With Solid Tumors Who Have Progressed on Anti-PD-(L)1 Therapy
Genome & Company
NCT04601402
sEphB4-HSA With RT+Chemo or Cetux in Patients With Intermediate to High Risk LAHNSCC
University of Colorado, Denver
NCT04091867
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 25 |
| Phase 2 | 9 |
| Phase 3 | 1 |
Top Sponsors
Named interventions
Most-linked intervention names on Squamous Cell Carcinoma of Head and Neck records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Squamous Cell Carcinoma of Head and Neck trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Squamous Cell Carcinoma of Head and Neck page
38 registered trials, 15 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 15 Squamous Cell Carcinoma of Head and Neck trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- NGM Biopharmaceuticals sponsors the most Squamous Cell Carcinoma of Head and Neck trials on record, review their full trial history before evaluating a specific study. See NGM Biopharmaceuticals's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Squamous Cell Carcinoma of Head and Neck condition card totals 38 registered trials; most-linked intervention Pembrolizumab; top US site state California. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.